glp-1 stomach paralysis law firm in michigan lawsuit gastroparesis office Ozempic for Blindness, and Injury Claims Chicago attorney Matt Williams discusses – Medicare GLP-1 Bridge Program Michigan

FDA labels for GLP-1 receptor agonists include warnings about increased risk of acute gallbladder disease, including cholecystitis and cholelithiasis, based on clinical trials and post-marketing data

The analysis found semaglutide drugs like Ozempic increased the risk of DVT by 266%

With heterogeneous evidence of the cardiovascular benefit, mortality, and potential risks of intensive glycemic control reported in several recent clinical trials, achieving good blood glucose control without increasing cardiovascular risk factors such as hypoglycemia and body weight gain is becoming more important [3,4,5,6,7]

Dehydration from these side effects can further compromise milk supply and maternal well-being

Actual product packaging may appear differently than shown